PMID- 17956601
OWN - NLM
STAT- MEDLINE
DCOM- 20080131
LR  - 20220310
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 7
DP  - 2007 Oct 23
TI  - Pharmacokinetic analysis of two different docetaxel dose levels in patients with 
      non-small cell lung cancer treated with docetaxel as monotherapy or with 
      concurrent radiotherapy.
PG  - 197
AB  - BACKGROUND: Previous pharmacokinetic studies with docetaxel have mostly used 
      3-weekly (75 mg/m2 and 100 mg/m2) or weekly regimens (35-40 mg/m2). The 
      pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m2 docetaxel, has 
      however not been well characterized. We examined the pharmacokinetics of weekly 
      docetaxel when administered with concurrent radiotherapy and compared the results 
      with a 3-weekly 100 mg/m2 regimen. METHODS: Thirty-four patients with non small 
      cell lung cancer (NSCLC) were included in this study, 19 receiving 100 mg/m2 
      docetaxel 3-weekly as single therapy, and 15 receiving 20 mg/m2 docetaxel weekly 
      with concurrent radiotherapy. A newly developed HPLC method was used for 
      measuring docetaxel levels, capable of quantifying docetaxel in plasma down to 
      the nanomolar level. RESULTS: The HPLC method showed detectable concentrations of 
      docetaxel in plasma even after 72 hours. In the present study we have 
      demonstrated that median docetaxel plasma levels of 3 nM can be obtained 72 hours 
      after a dose of 20 mg/m2. CONCLUSION: The pharmacokinetics of docetaxel is 
      characterized by great inter-individual variability and at some time points 
      plasma concentrations for 20 mg/m2 and 100 mg/m2 docetaxel were overlapping. 
      Extrapolation of these results indicates that radio sensitizing docetaxel 
      concentrations may be present for as long as 1 week, thus supporting the use of 
      20 mg/m2 weekly docetaxel.
FAU - Brunsvig, Paal F R
AU  - Brunsvig PF
AD  - Department of Medical Oncology, Cancer Clinic, Rikshospitalet-Radiumhospitalet 
      Medical Centre, Montebello, 0310 Oslo, Norway. p.f.brunsvig@medisin.uio.no
FAU - Andersen, Anders
AU  - Andersen A
FAU - Aamdal, Steinar
AU  - Aamdal S
FAU - Kristensen, Vessela
AU  - Kristensen V
FAU - Olsen, Harald
AU  - Olsen H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20071023
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Orosomucoid)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - *Antineoplastic Agents/administration & dosage/blood/pharmacokinetics
MH  - Area Under Curve
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/radiotherapy
MH  - Chromatography, High Pressure Liquid
MH  - Combined Modality Therapy
MH  - Docetaxel
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Orosomucoid/analysis
MH  - Radiotherapy
MH  - Reproducibility of Results
MH  - *Taxoids/administration & dosage/blood/pharmacokinetics
PMC - PMC2175508
EDAT- 2007/10/25 09:00
MHDA- 2008/02/01 09:00
PMCR- 2007/10/23
CRDT- 2007/10/25 09:00
PHST- 2007/03/13 00:00 [received]
PHST- 2007/10/23 00:00 [accepted]
PHST- 2007/10/25 09:00 [pubmed]
PHST- 2008/02/01 09:00 [medline]
PHST- 2007/10/25 09:00 [entrez]
PHST- 2007/10/23 00:00 [pmc-release]
AID - 1471-2407-7-197 [pii]
AID - 10.1186/1471-2407-7-197 [doi]
PST - epublish
SO  - BMC Cancer. 2007 Oct 23;7:197. doi: 10.1186/1471-2407-7-197.